MX2024004515A - Formas cristalinas de un benzimidazol sustituido que actua como inhibidor de cdk9 y sus usos. - Google Patents
Formas cristalinas de un benzimidazol sustituido que actua como inhibidor de cdk9 y sus usos.Info
- Publication number
- MX2024004515A MX2024004515A MX2024004515A MX2024004515A MX2024004515A MX 2024004515 A MX2024004515 A MX 2024004515A MX 2024004515 A MX2024004515 A MX 2024004515A MX 2024004515 A MX2024004515 A MX 2024004515A MX 2024004515 A MX2024004515 A MX 2024004515A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- acting
- substituted benzimidazole
- cdk9 inhibitor
- cdk9
- Prior art date
Links
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 title abstract 3
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 title abstract 3
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/12—Glutaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/14—Adipic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
- C07C65/10—Salicylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163255562P | 2021-10-14 | 2021-10-14 | |
| PCT/US2022/078143 WO2023064920A1 (en) | 2021-10-14 | 2022-10-14 | Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004515A true MX2024004515A (es) | 2024-07-01 |
Family
ID=84272325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004515A MX2024004515A (es) | 2021-10-14 | 2022-10-14 | Formas cristalinas de un benzimidazol sustituido que actua como inhibidor de cdk9 y sus usos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250011298A1 (enExample) |
| EP (1) | EP4416139A1 (enExample) |
| JP (1) | JP2024539631A (enExample) |
| KR (1) | KR20240115816A (enExample) |
| CN (1) | CN118355006A (enExample) |
| AU (1) | AU2022362075A1 (enExample) |
| CA (1) | CA3234907A1 (enExample) |
| IL (1) | IL312030A (enExample) |
| MX (1) | MX2024004515A (enExample) |
| WO (1) | WO2023064920A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220079851A (ko) * | 2019-09-11 | 2022-06-14 | 프렐루드 테라퓨틱스, 인코포레이티드 | Cdk 억제제 및 약제로서의 이의 용도 |
| WO2025076115A1 (en) * | 2023-10-02 | 2025-04-10 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| WO2025189114A1 (en) | 2024-03-08 | 2025-09-12 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220079851A (ko) | 2019-09-11 | 2022-06-14 | 프렐루드 테라퓨틱스, 인코포레이티드 | Cdk 억제제 및 약제로서의 이의 용도 |
-
2022
- 2022-10-14 KR KR1020247015784A patent/KR20240115816A/ko active Pending
- 2022-10-14 AU AU2022362075A patent/AU2022362075A1/en active Pending
- 2022-10-14 MX MX2024004515A patent/MX2024004515A/es unknown
- 2022-10-14 IL IL312030A patent/IL312030A/en unknown
- 2022-10-14 WO PCT/US2022/078143 patent/WO2023064920A1/en not_active Ceased
- 2022-10-14 EP EP22802453.5A patent/EP4416139A1/en not_active Withdrawn
- 2022-10-14 US US18/700,928 patent/US20250011298A1/en active Pending
- 2022-10-14 CA CA3234907A patent/CA3234907A1/en active Pending
- 2022-10-14 CN CN202280081352.7A patent/CN118355006A/zh active Pending
- 2022-10-14 JP JP2024522235A patent/JP2024539631A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240115816A (ko) | 2024-07-26 |
| CA3234907A1 (en) | 2023-04-20 |
| EP4416139A1 (en) | 2024-08-21 |
| WO2023064920A1 (en) | 2023-04-20 |
| JP2024539631A (ja) | 2024-10-29 |
| AU2022362075A1 (en) | 2024-05-09 |
| IL312030A (en) | 2024-06-01 |
| CN118355006A (zh) | 2024-07-16 |
| US20250011298A1 (en) | 2025-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004515A (es) | Formas cristalinas de un benzimidazol sustituido que actua como inhibidor de cdk9 y sus usos. | |
| CL2022002341A1 (es) | Compuestos y métodos para modular el empalme | |
| SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| ECSP19089214A (es) | Inhibidores de quinasa y usos de los mismos | |
| UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| DOP2019000040A (es) | Compuestos de pirrolizina sustituidas y usos de los mismos | |
| CL2018002794A1 (es) | Compuestos bicíclicos | |
| CO2019006687A2 (es) | Polimorfos | |
| CO2022012594A2 (es) | Inhibidores del eif4e y sus usos | |
| UY36781A (es) | Fenoxihalogenofenilamidinas y su uso como fungicidas | |
| CL2019001736A1 (es) | Polimorfos. | |
| MX2020007531A (es) | Aminopirrolotriazinas como inhibidores de cinasa. | |
| NI201900075A (es) | Compuesto moduladores del receptor de hidrocarburos de arilo (ahr) | |
| CL2019003213A1 (es) | Compuestos plaguicidas bicíclicos. | |
| CL2018000182A1 (es) | Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos | |
| MX2019010642A (es) | Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos. | |
| CL2022001456A1 (es) | Tiofenocarboxamidas sustituidas y sus derivados | |
| CR20160224A (es) | Composición herbicida que comprende inhibidores ACC | |
| CL2018002023A1 (es) | Uso de moduladores de receptores de gabaa para el tratamiento de picor. | |
| NI202000042A (es) | Polimorfos | |
| CL2022001594A1 (es) | Tiofenocarboxamidas sustituidas y sus derivados | |
| CO2020001861A2 (es) | Inhibidores de ror gamma | |
| MX2016015106A (es) | Derivados de dipicolilamina y sus usos farmaceuticos. | |
| UY38759A (es) | Tienilhidroxiisoxazolinas y derivados de las mismas | |
| CL2018003872A1 (es) | Sales cristalinas del inhibidor de inmunoproteasoma de péptido epoxicetona. |